DSpace Repository

Bombesin receptor subtype-3 (BRS-3), a novel candidate as therapeutic molecular target in obesity and diabetes

Show simple item record

APA

Ramos Álvarez, Irene & Martín Duce, Antonio & Moreno Villegas, Zaida & Sanz, Raúl & Aparicio, César & Portal Núñez, Sergio & Mantey, Samuel A. & Jensen, Robert T. & González, Nieves (2013-01 ) .Bombesin receptor subtype-3 (BRS-3), a novel candidate as therapeutic molecular target in obesity and diabetes.

ISO 690

Ramos Álvarez, Irene & Martín Duce, Antonio & Moreno Villegas, Zaida & Sanz, Raúl & Aparicio, César & Portal Núñez, Sergio & Mantey, Samuel A. & Jensen, Robert T. & González, Nieves. 2013-01 .Bombesin receptor subtype-3 (BRS-3), a novel candidate as therapeutic molecular target in obesity and diabetes.

https://hdl.handle.net/20.500.12080/39595
dc.contributor.author Ramos Álvarez, Irene
dc.contributor.author Martín Duce, Antonio
dc.contributor.author Moreno Villegas, Zaida
dc.contributor.author Sanz, Raúl
dc.contributor.author Aparicio, César
dc.contributor.author Portal Núñez, Sergio
dc.contributor.author Mantey, Samuel A.
dc.contributor.author Jensen, Robert T.
dc.contributor.author González, Nieves
dc.date.accessioned 2024-02-08T14:03:03Z
dc.date.available 2024-02-08T14:03:03Z
dc.date.created 2013-01
dc.date.issued 2013-01
dc.identifier.uri https://hdl.handle.net/20.500.12080/39595
dc.description.abstract BRS-3 KO-mice developed obesity and unbalanced glucose metabolism, suggesting an important role of BRS-3 receptor in glucose homeostasis. We explored BRS-3 expression in skeletal muscle from normal, obese or type-2 diabetic (T2D) patients, and the effect of [D-Phe6 , b-Ala11, Phe13,Nle14]bombesin6¿14¿ BRS-3-agonist-peptide (BRS-3-AP) ¿ on glucose-related effects, before or after BRS-3 gene silencing. In muscle tissue and primary cultured myocytes from altered metabolic states, BRS-3 gene/protein expres sions were down-regulated. In normal, obese and T2D cells: A) BRS-3-AP as insulin enhanced BRS-3 and GLUT-4 mRNA/protein levels; improving glucotransporter translocation to plasma membrane, and B) BRS-3-AP caused a concentration-related-stimulation of glucose transport, being obese and T2D myo cytes more sensitive to the ligand than normal. Wortmannin and PD98059, but not rapamycin, abolished the stimulatory action of BRS-3-AP on glucose transport. BRS-3 plays an important role in glucose metab olism, and could be use as a molecular target, and/or its ligand, as a therapeutic agent for obesity and dia betes treatments. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title Bombesin receptor subtype-3 (BRS-3), a novel candidate as therapeutic molecular target in obesity and diabetes es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/restrictedAccess es_ES
dc.identifier.location N/A es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

CC-BY Except where otherwise noted, this item's license is described as CC-BY

Search DSpace


Browse

My Account

Social Media